Table 2.
Cancer | Immune Suppressive Cells | Treatments, Future Treatments or Other Uses | References | |
---|---|---|---|---|
Tregs | MDSCs | |||
Large B cell lymphoma | ○ | prognostic biomarker | Ahearne et al. [44] | |
Non-Hodgkin Lymphoma | ○ | prognostic biomarker | Pinheiro et al. [45] | |
Myeloma | ○ | CTLA-4 antibody | Braga et al. [46] | |
○ | ○ | High-dose IL2 followed by Sorafenib | Monk et al. [47] | |
○ | Adjuvant GM-CSF | Daud et al. [48] | ||
○ | ○ | prognostic marker | Brimnes et al. [49] | |
Ovarian Cancer | ○ | prognostic biomarker | Brtnicky et al. [50] | |
Mouse model (liver metastasis model) | ○ | Anti-PD-L1 antibody | Ilkovitch et al. [51] | |
Esophageal Cancer | ○ | Down-regulation of B7-H1 expression | Chen et al. [52] | |
non-small-cell lung cancer | ○ | prognostic biomarker | Hasegawa et al. [53] | |
Yukawa et al. [54] | ||||
○ | prognostic biomarker | Liu et al. [43] | ||
Lewis lung carcinoma (mouse model) | ○ | anti-miR214 | Yin et al. [55] | |
Pancreatic ductal adenocarcinoma | ○ | prognostic biomarker | Luardi et al. [57] | |
Renal Cell Carcionam | ○ | ○ | High-dose IL2 followed by Sorafenib | Monk et al. [47] |
○ | prognostic biomarker | Mirza et al. [58] | ||
○ | prognostic biomarker | Kusmartsev et al. [59] | ||
Solitary Fibrous Tumor | ○ | Sunitinib malate | Tazzari et al. [60] | |
Thyroid cancer | ○ | Inhibition of FOXP3 | Chu et al. [61] | |
Glioblastoma | ○ | prognostic marker | Soyour E et al. [62] | |
Colon carcinoma (mouse model) | ○ | ○ | c-kit antibody | Pan et al. [63] |